Steven Attia

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:45-51. 2009
  2. ncbi Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
    Jill Kolesar
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:79-86. 2009
  3. ncbi Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
    J Thorac Oncol 3:1018-25. 2008
  4. ncbi Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
    Howard H Bailey
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue K4 6 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:149-57. 2008
  5. ncbi Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Clin Cancer Res 14:2437-43. 2008
  6. ncbi Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma
    Steven Attia
    Department of Medicine, Section of Hematology and Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
    Clin Adv Hematol Oncol 6:44-54. 2008
  7. ncbi A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 528, Madison, WI 53792, USA
    Invest New Drugs 26:369-79. 2008

Detail Information

Publications7

  1. ncbi Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:45-51. 2009
    ..To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine...
  2. ncbi Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
    Jill Kolesar
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:79-86. 2009
    ..The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP...
  3. ncbi Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA
    J Thorac Oncol 3:1018-25. 2008
    ..Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents together as palliative treatment for older patients with advanced NSCLC...
  4. ncbi Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
    Howard H Bailey
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue K4 6 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:149-57. 2008
    ..We conducted a phase II multi-institutional study of oral POH administered four times daily in women with advanced treatment-refractory breast cancer...
  5. ncbi Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Clin Cancer Res 14:2437-43. 2008
    ..Doxercalciferol (1 alpha-hydroxyvitamin D2) had modest activity in phase I/II trials. Preclinical data support combining vitamin D analogues with docetaxel to treat AIPC...
  6. ncbi Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma
    Steven Attia
    Department of Medicine, Section of Hematology and Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
    Clin Adv Hematol Oncol 6:44-54. 2008
    ..Animal models suggest that growth hormone participates in hepatocarcinogenesis...
  7. ncbi A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 528, Madison, WI 53792, USA
    Invest New Drugs 26:369-79. 2008
    ..In conclusion, this regimen appears inactive against predominantly GR pancreatic cancer. RR M2 protein may not have a critical role in the malignant potential of pancreatic cancer...